Literature DB >> 20179005

Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.

Sascha David1, Philipp Kümpers, Alexander Lukasz, Danilo Fliser, Jens Martens-Lobenhoffer, Stefanie M Bode-Böger, Volker Kliem, Hermann Haller, Jan T Kielstein.   

Abstract

BACKGROUND: Angiopoietin-2 (Ang-2) is an antagonistic ligand of the endothelial-specific Tie2 receptor. Patients on dialysis have markedly elevated Ang-2 levels, and those correlate with their atherosclerotic burden. The aim of the current study was to investigate the relationship between the circulating levels of Ang-2 and renal function throughout all stages of chronic kidney disease (CKD). In addition, we aimed to detect a potential link between the nitric oxide (NO) synthase inhibitor asymmetric dimethylarginine (ADMA) and the Ang-2 levels.
METHODS: Glomerular filtration rate (GFR) was assessed by the inulin clearance technique ((i)GFR) and compared to serum Ang-2 (immunoluminometric assay) and ADMA levels (liquid chromatography-electrospray tandem mass spectrometry) in 44 untreated non-smokers at the different stages of CKD 1-4. Ang-2 was also measured in 19 patients on dialysis (CKD stage 5). In addition, the Ang-2 and (c)GFR (cystatin C) measurements were taken in 15 healthy individuals before and 72 h after kidney donation.
RESULTS: The median Ang-2 levels steadily increased across the following groups: healthy controls: 0.77 (0.32-1.08) ng/mL; CKD 1: 0.83 (0.67-1.09) ng/mL; CKD 2: 0.93 (0.74-1.15) ng/mL; CKD 3: 1.13 (0.87-1.49) ng/mL; CKD 4: 1.75 (1.23-2.61) ng/mL; and CKD 5: 4.87 (3.22-7.59) ng/mL, respectively (non-parametric ANOVA P < 0.0001). Ang-2 was associated with the degree of CKD as evidenced by an inverse correlation with the (i)GFR (r = -0.509, P < 0.0001) and positive correlations with homocysteine (r = 0.365, P = 0.015) and phosphate (r = 0.53, P < 0.0001). Additionally, Ang-2 correlated with the ADMA levels (r = 0.35, P = 0.01). We detected a close inverse correlation between the mean changes in GFR and circulating Ang-2 at 72 h after kidney donation (r = -0.54, P = 0.03).
CONCLUSIONS: Circulating Ang-2, a putative marker and potential mediator of accelerated atherosclerosis, is inversely related to GFR and increases with advanced CKD. The correlation between Ang-2 and ADMA points towards the hypothesis that the ADMA-driven NO deficiency might trigger Ang-2 release and account for the Ang-2 increase in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179005     DOI: 10.1093/ndt/gfq060

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  33 in total

1.  The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.

Authors:  Melahat Coban; Ayca Inci
Journal:  Int Urol Nephrol       Date:  2018-04-13       Impact factor: 2.370

Review 2.  Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.

Authors:  Sazan Rasul; Ludwig Wagner; Alexandra Kautzky-Willer
Journal:  Endocrine       Date:  2012-07-21       Impact factor: 3.633

3.  Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.

Authors:  David M Charytan; Robert Padera; Alexander M Helfand; Michael Zeisberg; Xingbo Xu; Xiaopeng Liu; Jonathan Himmelfarb; Angeles Cinelli; Raghu Kalluri; Elisabeth M Zeisberg
Journal:  Int J Cardiol       Date:  2014-07-06       Impact factor: 4.164

4.  Soluble thrombomodulin reduces inflammation and prevents microalbuminuria induced by chronic endothelial activation in transgenic mice.

Authors:  Gangaraju Rajashekhar; Akanksha Gupta; Abby Marin; Jessica Friedrich; Antje Willuweit; David T Berg; Martin S Cramer; George E Sandusky; Timothy A Sutton; David P Basile; Brian W Grinnell; Matthias Clauss
Journal:  Am J Physiol Renal Physiol       Date:  2011-11-30

5.  Angiopoietin-2-induced arterial stiffness in CKD.

Authors:  Fan-Chi Chang; Wen-Chih Chiang; Ming-Hsuan Tsai; Yu-Hsiang Chou; Szu-Yu Pan; Yu-Ting Chang; Pei-Ying Yeh; Yi-Ting Chen; Chih-Kang Chiang; Yung-Ming Chen; Tzong-Shinn Chu; Kwan-Dun Wu; Shuei-Liong Lin
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

6.  Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy.

Authors:  Kathryn M Gores; Angela S Delsing; Sara J Kraus; Linda Powers; Daniel A Vaena; Mohammed M Milhem; Martha Monick; Kevin C Doerschug
Journal:  Shock       Date:  2014-08       Impact factor: 3.454

7.  Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study.

Authors:  Sazan Rasul; Marie Helene Reiter; Aysegul Ilhan; Katharina Lampichler; Ludwig Wagner; Alexandra Kautzky-Willer
Journal:  Cardiovasc Diabetol       Date:  2011-06-23       Impact factor: 9.951

8.  Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.

Authors:  Paul A Monach; Philipp Kümpers; Alexander Lukasz; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Simon Carette; Linna Ding; Gary S Hoffman; David Iklé; Cees G M Kallenberg; Nader A Khalidi; Carol A Langford; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Marion Haubitz; Peter A Merkel
Journal:  PLoS One       Date:  2012-01-18       Impact factor: 3.240

9.  Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis.

Authors:  Rukshana C Shroff; Karen L Price; Maria Kolatsi-Joannou; Alexandra F Todd; David Wells; John Deanfield; Richard J Johnson; Lesley Rees; Adrian S Woolf; David A Long
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

10.  Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease.

Authors:  Fan-Chi Chang; Tai-Shuan Lai; Chih-Kang Chiang; Yung-Ming Chen; Ming-Shiou Wu; Tzong-Shinn Chu; Kwan-Dun Wu; Shuei-Liong Lin
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.